Swiss - Delayed Quote CHF

Basilea Pharmaceutica AG (BSLN.SW)

42.10

-0.75

(-1.75%)

At close: January 10 at 5:30:32 PM GMT+1

Basilea provides portfolio update and outlook

Allschwil, Switzerland, January 08, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today on the progress of its Research & Development portfolio in 2024 and upcoming milestones. David Veitch, Chief Executive Officer, said: “We have achieved several significant milestones in 2024. We partnered with a highly committed, focused and capable company for

GlobeNewswire 3 days ago

BPMUF
Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics

Additional funding awarded following successful drug candidate nominationUSD 7.3 million to support progression of antibiotic BAL2420 (LptA inhibitor) towards first-in-human clinical studies Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 23, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it was awarded an ad

GlobeNewswire 19 days ago

BPMUF
Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, December 16, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an exclusive distribution and license agreement with Innoviva Specialty Therapeutics, Inc., a wholly owned subsidiary of Innoviva Inc. (NASDAQ: INVA), for the commercialization of Basilea’s h

GlobeNewswire 26 days ago

BPMUF
Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis

Allschwil, Switzerland, September 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has initiated the Fosmanogepix Against Standard-of-care Treatment in Invasive Candidiasis (FAST-IC) phase 3 study. This registrational study evaluates the efficacy and safety of Basilea’s broad-spectrum antifungal fosmanogepix in the treatment of adu

GlobeNewswire 3 months ago

BPMUF
Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding

Initial funding of USD 29 million to support development of Basilea’s clinical stage first-in-class antifungals, fosmanogepix and BAL2062Multi-year Other Transaction Agreement (OTA) allows for potential funding of up to approximately USD 268 million to develop antifungal and antibacterial assets Increasing FY 2024 financial guidance on total revenue, operating result and net profit Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 19, 2024 Basilea Pharmaceutica Ltd, Al

GlobeNewswire 3 months ago

BPMUF
Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, September 6, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that sales of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer in Europe exceeded the threshold that triggered a milestone payment of USD 25 million to Basilea. David Veitch, Chief Executive Off

GlobeNewswire 4 months ago

BPMUF
European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 27, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the European Commission (EC) has extended the indications of the antifungal Cresemba® (isavuconazole) to pediatric patients and also granted an extension of market exclusivity by two additional years, which trigge

GlobeNewswire 4 months ago

BPMUF
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

Allschwil, Switzerland, August 21, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 1.25 million milestone payment. David Veitch, Basilea’s

GlobeNewswire 4 months ago

BPMUF
Recent Price Trend in Basilea Pharmaceutica (BPMUF) is Your Friend, Here's Why

Basilea Pharmaceutica (BPMUF) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks 4 months ago

BPMUF
Basilea reports strong 2024 half-year results and significantly increases full-year revenue and profit guidance

Continued success of Cresemba® with 16.6% growth of royalties to CHF 42.8 million Operating result of CHF 9.3 million, net profit of CHF 20.7 millionTotal revenue guidance increased by 7% to CHF ~196 million and operating profit guidance increased by 20% to CHF ~36 million Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, August 13, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with

GlobeNewswire 4 months ago

BPMUF
Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation

Allschwil, Switzerland, June 20, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement with the Glioblastoma Foundation Inc., for Basilea’s oncology drug candidate lisavanbulin (BAL101553), which has been developed as a potential therapy for glioblastoma, the most common type of primary brain can

GlobeNewswire 6 months ago

BPMUF
Basilea Pharmaceutica (BPMUF) Is a Great Choice for 'Trend' Investors, Here's Why

If you are looking for stocks that are well positioned to maintain their recent uptrend, Basilea Pharmaceutica (BPMUF) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks 7 months ago

BPMUF
Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024

Allschwil, Switzerland, May 03, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that scientific presentations with new data on its antibiotic ceftobiprole (Zevtera®) have been presented at ESCMID Global 2024, the annual meeting of the European Society of Clinical Microbiology and Infectious Diseases, which took place from April 27 to 30, 2024

GlobeNewswire 8 months ago

BPMUF
Basilea shareholders approve all proposals of the board of directors at the annual general meeting

Allschwil, Switzerland, April 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported that shareholders approved all proposals of the board of directors at today’s annual general meeting (AGM) for the financial year 2023. At the AGM, the shareholders approved the annual report, the financial statements and the consolidated financial statements for the f

GlobeNewswire 8 months ago

BPMUF
Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics

Allschwil, Switzerland, April 09, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has been awarded a grant from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to supporting the early development of antibacterial products. The grant award is to support initial p

GlobeNewswire 8 months ago

BPMUF
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 04, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the US Food and Drug Administration (FDA) approved ZEVTERA® (ceftobiprole medocaril sodium for injection), for the treatment of adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), i

GlobeNewswire 9 months ago

BPMUF
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

Allschwil, Switzerland, March 11, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales performance of the antifungal Cresemba® (isavuconazole) by its license partner Pfizer Inc. in the Asia Pacific region and China exceeded the sales threshold triggering a USD 1.25 million milestone payment. David Veitch, Basilea’s

GlobeNewswire 9 months ago

BPMUF
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio

Increased Cresemba® and Zevtera®-related revenue of CHF 150.3 million (+22.9% year-on-year) at upper end of guidanceOperating profit of CHF 19.2 million and net profit of CHF 10.5 million, significantly above guidanceAddition of three new anti-infective assets to clinical portfolio, including phase-3-ready antifungal fosmanogepixStrong cash and restricted cash position of CHF 64.3 million, after fully absorbing investments into portfolio expansion and accelerated debt reduction FY 2024 guidance:

GlobeNewswire 10 months ago

BPMUF
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea

Allschwil, Switzerland, January 19, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the sales of the antifungal Cresemba® (isavuconazole) in 2023 by its partner Knight Therapeutics Inc. (“Knight”, TSX: GUD) in Latin America exceeded the threshold triggering the first sales milestone payment for this region. David Veitch, Chief Executive

GlobeNewswire 11 months ago

BPMUF
Basilea announces acquisition of preclinical antibiotics program from Spexis

Novel class of antibioticsBactericidal activity demonstrated in vitro and in vivo against broad range of Gram-negative bacteria, including multidrug-resistant strains Allschwil, Switzerland, January 15, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement with Spexis AG (SIX: SPEX) for a preclin

GlobeNewswire 11 months ago

BPMUF

Performance Overview

Return	BSLN.SW	MSCI WORLD
YTD	+1.81%	-1.09%
1-Year	+15.18%	+16.88%
3-Year	+5.25%	0.00%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Basilea Pharmaceutica AG (BSLN.SW)

Basilea provides portfolio update and outlook

Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics

Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States

Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis

Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding

Strong Cresemba® (isavuconazole) sales performance in Europe triggers USD 25 million sales milestone payment to Basilea

European Commission Decision to approve the pediatric use of antifungal Cresemba® (isavuconazole) and extension of market exclusivity triggers CHF 10 million milestone payment to Basilea

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

Recent Price Trend in Basilea Pharmaceutica (BPMUF) is Your Friend, Here's Why

Basilea reports strong 2024 half-year results and significantly increases full-year revenue and profit guidance

Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation

Basilea Pharmaceutica (BPMUF) Is a Great Choice for 'Trend' Investors, Here's Why

Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024

Basilea shareholders approve all proposals of the board of directors at the annual general meeting

Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics

Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications

Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea

Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio

Cresemba® sales in Latin America trigger first sales milestone payment to Basilea

Basilea announces acquisition of preclinical antibiotics program from Spexis

Performance Overview